Article

Daily Medication Pearl: Belzutifan (Welireg)

Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors.

Medication Pearl of the Day: Belzutifan (Welireg)

Indication: Belzutifanis a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.

Insight:

  • Dosing: The recommended dosage of belzutifanis 120 mg administered orally once daily with or without food.
  • Dosage forms:Tablets 40 mg.
  • Adverse events (AEs): The most common (≥ 25%) AEs, including laboratory abnormalities, were decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.
  • Mechanism of action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). HIF-2α is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia.
  • Manufacturer: Merck

Sources:

Related Videos
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com
Older patient with medical health checkup with cardiologist or geriatric doctor. Woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com